CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 122 enrolled
Drug / intervention
TS022 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00914186
NCT00914186Phase 2Completed

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adult Patients With a Diagnosis of Atopic Dermatitis (AD) With Moderate to Very Severe Pruritus

Taisho Pharmaceutical R&D Inc.·interventional·Posted Jun 4, 2009·Updated Dec 1, 2011

In Brief

A Phase 2 clinical trial evaluating TS022 and Vehicle for Atopic Dermatitis. Completed, enrolled 122 participants across 15 sites.

Detailed Summary

The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen of twice-daily topical application.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 4, 2009
Enrollment StartJun 1, 2009
Primary CompletionMay 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.1 years ago

Interventions

TS022drug

Lotion

Vehicledrug

Lotion